Daxor Corp DXR
We take great care to ensure that the data presented and summarized in this overview for DAXOR CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DXR
View all-
Vanguard Group Inc Valley Forge, PA48.8KShares$400,3890.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8KShares$121,5320.0% of portfolio
-
Keyes, Stange & Wooten Wealth Management, LLC Palm Coast, FL14.6KShares$119,8180.07% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ7.2KShares$59,0390.0% of portfolio
-
Ubs Group Ag1.24KShares$10,1350.0% of portfolio
-
Princeton Global Asset Management LLC500Shares$4,1000.0% of portfolio
-
Jones Financial Companies Lllp100Shares$8190.0% of portfolio
-
Jpmorgan Chase & CO New York, NY5Shares$410.0% of portfolio
-
Morgan Stanley New York, NY1Shares$80.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in DXR
Top Purchases
Top Sells
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Insider Transactions at DXR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2024
|
Jonathan Adam Feldschuh Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
32,000
+47.12%
|
-
|
|
Dec 06
2024
|
Michael Richard Feldschuh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
45,000
+17.82%
|
-
|
|
Mar 27
2024
|
Robert J Michel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
750
+6.22%
|
$6,000
$8.7 P/Share
|
|
Mar 04
2024
|
Edward Feuer Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$7,000
$7.21 P/Share
|
|
Dec 06
2023
|
Robert J Michel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
120
+1.12%
|
$840
$7.75 P/Share
|
|
Dec 01
2023
|
Robert J Michel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
180
+1.7%
|
$1,260
$7.75 P/Share
|
|
Dec 01
2023
|
Michael Richard Feldschuh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
800
+0.49%
|
$5,600
$7.8 P/Share
|
|
Nov 24
2023
|
Robert J Michel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
500
+4.65%
|
$3,500
$7.94 P/Share
|
|
Nov 21
2023
|
Michael Richard Feldschuh Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84
+0.05%
|
$588
$7.65 P/Share
|
|
Nov 10
2023
|
Michael Richard Feldschuh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,001
+0.62%
|
$7,007
$7.83 P/Share
|
|
Nov 09
2023
|
Michael Richard Feldschuh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
401
+0.25%
|
$2,807
$7.85 P/Share
|
|
Oct 31
2023
|
Robert J Michel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+17.02%
|
-
|
|
Oct 13
2023
|
Robert J Michel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
500
+6.06%
|
$4,500
$9.02 P/Share
|
|
Sep 18
2023
|
Of Joseph Feldschuh Estate > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
25,000
-0.97%
|
-
|
|
May 24
2023
|
Joy S. Goudie Director |
BUY
Open market or private purchase
|
Direct |
300
+50.0%
|
$2,700
$9.75 P/Share
|
|
May 24
2023
|
Michael Richard Feldschuh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+1.23%
|
$18,000
$9.75 P/Share
|
|
Mar 27
2023
|
Robert J Michel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,750
+23.99%
|
-
|
|
Nov 18
2022
|
Robert J Michel Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+12.12%
|
$10,000
$10.0 P/Share
|
|
Nov 17
2022
|
Caleb Des Rosiers Director |
BUY
Open market or private purchase
|
Direct |
3,157
+50.0%
|
$28,413
$9.5 P/Share
|
|
Jun 10
2021
|
Robert J Michel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+24.24%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 78.8K shares |
|---|